Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
24 hedge funds and large institutions have $226K invested in Navidea Biopharmaceuticals Inc. in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 3 closing their positions.
615% more capital inflows, than outflows
Capital inflows: $109K | Capital outflows: $15.3K
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
4% more funds holding
Funds holding: 23 → 24 (+1)
3.07% more ownership
Funds ownership: 4.58% → 7.66% (+3.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Virtu Financial
New York
|
+$30.9K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$24.9K |
| 3 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$18.1K |
| 4 |
ACM
Allred Capital Management
Dallas,
Texas
|
+$16K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$13.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$11.6K |
| 2 |
Two Sigma Securities
New York
|
-$2.58K |
| 3 |
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$920 |
| 4 |
JP Morgan Chase
New York
|
-$172 |
| 5 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$10 |
NAVB Hedge Fund Activity: Q3 2023 in Review
24 of the 6,316 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q3 2023, worth a combined $226K — up 63% from $139K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new NAVB positions and 3 closed out — a net gain of 1 holder — while 6 added to existing stakes and 2 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $30.9K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $11.6K sold.
- 24 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q3 2023, up from 23 in Q2 2023.
- Funds reported $226K of Navidea Biopharmaceuticals Inc. stock for Q3 2023, up 63% quarter-over-quarter.
- 4 funds opened new Navidea Biopharmaceuticals Inc. positions in Q3 2023 and 3 closed out, a net change of +1 holder.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q3 2023 was Virtu Financial, an estimated $30.9K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q3 2023 was Susquehanna International Group, an estimated $11.6K sold.
Based on aggregated 13F filings for Q3 2023.